Mesa Laboratories Reports Q2 FY2027: EPS of $0.75 and Revenue of $62.34M Exceed Estimates
Operational Improvements at SDC and Debt Reduction Highlight the Quarter, Offset by Weakness at Clinical Genomics and Biopharmaceutical Development Related Stocks: MLAB ,